APA (7th ed.) Citation

Choe, J., Prodanovic, N., Niebrzydowski, J., Staykov, I., Dokoupilova, E., Baranauskaite, A., . . . Smolen, J. S. (2017). A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Annals of the rheumatic diseases, 76(1), 58-64. https://doi.org/10.1136/annrheumdis-2015-207764

Chicago Style (17th ed.) Citation

Choe, Jung-Yoon, et al. "A Randomised, Double-blind, Phase III Study Comparing SB2, an Infliximab Biosimilar, to the Infliximab Reference Product Remicade in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy." Annals of the Rheumatic Diseases 76, no. 1 (2017): 58-64. https://doi.org/10.1136/annrheumdis-2015-207764.

MLA (9th ed.) Citation

Choe, Jung-Yoon, et al. "A Randomised, Double-blind, Phase III Study Comparing SB2, an Infliximab Biosimilar, to the Infliximab Reference Product Remicade in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy." Annals of the Rheumatic Diseases, vol. 76, no. 1, 2017, pp. 58-64, https://doi.org/10.1136/annrheumdis-2015-207764.